Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRN163L + trastuzumab
- Development stage
- Unknown
- Lead developer
- Geron
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
GRN163L (imetelstat) is a synthetic lipid-conjugated 13-mer oligonucleotide that acts as a telomerase inhibitor by targeting the RNA template region of human telomerase, thereby inhibiting its activity. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain breast and gastric cancers. The combination of GRN163L and trastuzumab has been investigated for overcoming resistance to HER2-targeted therapy in HER2-positive breast cancer, with preclinical studies suggesting enhanced efficacy against cancer stem cell populations. GRN163L was developed by Geron, while trastuzumab was originally developed by Genentech/Roche and is available under several brand names[1][5][8].
- Brand names
- HerceptinHerzumaKanjintiOgivriOntruzantTrazimeraHercessi
- Other names
- trastuzumab
02
Targets
Telomerase (Human telomerase)
Beyond the preview
Go deeper on GRN163L + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRN163L + trastuzumab.